SCHEMBL9967386

SCHEMBL9967386

CNc1cc(-n2ncc(C(=O)O)c2N)ncn1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 5/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
JAK2 O60674 2/20 0.39
MAPK14 Q16539 4/20 0.38
POLB P06746 1/20 0.38
NNMT P40261 2/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
PTPN1 P18031 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9970942 0.79 MAPT (0.46) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL3580927 0.79 NPC1 (0.44) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL28943666 0.73 NPC1 (0.49) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL27700559 0.72 NPC1 (0.45) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL3016436 0.71 MAPT (0.46) ALDH1A1MAPTCYP1A2CYP2C19LMNA
SCHEMBL3580930 0.71 NPC1 (0.43) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL23657848 0.69 NPC1 (0.58) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL27700542 0.69 NPC1 (0.44) NPC1RAB9AALDH1A1MAPTMAPK14
SCHEMBL3591023 0.69 MAPT (0.47) NPC1RAB9AALDH1A1MAPTCYP1A2
SCHEMBL27681340 0.69 TSHR (0.47) NPC1RAB9AALDH1A1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK NPC1 3863/4885RAB9A 1272/4885ALDH1A1 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.